Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
10/20/25 Adlai Nortye Biopharma (ANL) Buparlisib for Head and Neck Cancer Subscribers Only Subscribers Only Subscribers Only
10/20/25 Roche (RO) Tecentriq for Bladder Cancer Subscribers Only Subscribers Only Subscribers Only
10/20/25 Perspective Therapeutics (CATX) VMT-𝛼-NET for Neuroendocrine Tumors (NET) Subscribers Only Subscribers Only Subscribers Only
10/20/25 Amgen (AMGN) Bemarituzumab for Gastric Cancer Subscribers Only Subscribers Only Subscribers Only
10/19/25 Johnson & Johnson (JNJ) Amivantamab SC for Head and Neck Cancer Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
01/31/2025 Subscribers Only Subscribers Only Trial Announcement - Initiation
01/31/2025 Subscribers Only Subscribers Only Trial Announcement - Initiation
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update